Healthcare
Live Price
Offline$54.69
-0.60% today
Window Change
-4.54%
Window
May 29, 2026 โ Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BioMarin Pharmaceutical Inc. (BMRN) is a Healthcare stock with a market cap of $10.24B. The stock last traded around $54.69 and down 4.5% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of +12.9%, EPS growth of -19.1%, a dividend yield of 0.0%. What stands out right now is revenue +12.9%, EPS -19.1%, free cash flow +52.5% with operating margin 13.8% and ROIC 4.0%. Valuation already assumes a fairly strong business story at P/E 38.1 and price/sales 3.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines BMRN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+12.9% vs +7.6% peer median
Operating Margin
Below sector median
+13.8% vs +19.4% peer median
P/E
Near sector median
38.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +12.9% and EPS is at -19.1%, with operating margin around 13.8%.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BMRN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BMRN Max Drawdown
-6.93%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for BMRN and SPY.
Company Overview
BioMarin Pharmaceutical Inc.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.